Next Article in Journal
Salt-Mediated Au-Cu Nanofoam and Au-Cu-Pd Porous Macrobeam Synthesis
Previous Article in Journal
Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
Molecules 2018, 23(7), 1700; https://doi.org/10.3390/molecules23071700

Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro

1
Nanotechnology Characterization Lab, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
2
Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, POB 12272, Jerusalem 9112102, Israel
3
Nanomedicine Research and Education Center, Institute of Pathophysiology, Semmelweis University, 1089 Budapest, Hungary
4
SeroScience Ltd., Nagyvárad tér 4, 1089 Budapest, Hungary
5
Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc University, 3515 Miskolc, Hungary
*
Author to whom correspondence should be addressed.
Received: 20 June 2018 / Revised: 6 July 2018 / Accepted: 10 July 2018 / Published: 12 July 2018
(This article belongs to the Section Nanochemistry)
Full-Text   |   PDF [3491 KB, uploaded 12 July 2018]   |  

Abstract

Infusion reactions (IRs) are common immune-mediated side effects in patients treated with a variety of drug products, including, but not limited to, nanotechnology formulations. The mechanism of IRs is not fully understood. One of the best studied mechanisms of IRs to nanomedicines is the complement activation. However, it is largely unknown why some patients develop reactions to nanomedicines while others do not, and why some nanoparticles are more reactogenic than others. One of the theories is that the pre-existing anti-polyethylene glycol (PEG) antibodies initiate the complement activation and IRs in patients. In this study, we investigated this hypothesis in the case of PEGylated liposomal doxorubicin (Doxil), which, when used in a clinical setting, is known to induce IRs; referred to as complement activation-related pseudoallergy (CARPA) in sensitive individuals. We conducted the study in vitro using plasma derived from C57BL/6 mice and twenty human donor volunteers. We used mouse plasma to test a library of well-characterized mouse monoclonal antibodies with different specificity and affinity to PEG as it relates to the complement activation by Doxil. We determined the levels of pre-existing polyclonal antibodies that bind to PEG, methoxy-PEG, and PEGylated liposomes in human plasma, and we also assessed complement activation by Doxil and concentrations of complement inhibitory factors H and I in these human plasma specimens. The affinity, specificity, and other characteristics of the human polyclonal antibodies are not known at this time. Our data demonstrate that under in vitro conditions, some anti-PEG antibodies contribute to the complement activation by Doxil. Such contribution, however, needs to be considered in the context of other factors, including, but not limited to, antibody class, type, clonality, epitope specificity, affinity, and titer. In addition, our data contribute to the knowledge base used to understand and improve nanomedicine safety. View Full-Text
Keywords: nanoparticles; liposomes; complement activation; CARPA; hypersensitivity; infusion reaction; immunotoxicity; anti-PEG antibody nanoparticles; liposomes; complement activation; CARPA; hypersensitivity; infusion reaction; immunotoxicity; anti-PEG antibody
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Neun, B.W.; Barenholz, Y.; Szebeni, J.; Dobrovolskaia, M.A. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro. Molecules 2018, 23, 1700.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top